SLRPNK

1,339 readers
161 users here now

What is Solarpunk?

A SolarPunk Manifesto

Basic Rules:

be constructive: there is no need of another internet space full of competition, negativity, rage etc.;
no bigotry, including racism, sexism, ableism, transphobia, homophobia or xenophobia;
be empathic: empathy is more rebellious than a middle finger;
no porn and no gore: let's keep this place easy to manage;
no ads / spamming / flooding, we don't want to buy/consume your commodified ideas;
occasional self-promotion by active members is fine.

For any community related question or to just test some function: !meta@slrpnk.net

Try our Photon & Alexandrite frontends.

Or try our lightweight UI and Voyager mobile UI.

All accounts also work with XMPP chat automatically incl. our Movim client.

If you need to jointly brainstorm on your next Solarpunk text, try our Etherpad.

And don't miss our Wiki.

founded 2 years ago

ADMINS

Trial results for new lung cancer drug are ‘off the charts’, say doctors (www.theguardian.com)

submitted 3 months ago by fossilesque@mander.xyz to c/medicine@mander.xyz

0 comments fedilink

225

Trial results for new lung cancer drug are ‘off the charts’, say doctors (www.theguardian.com)

submitted 3 months ago by girlfreddy@lemmy.ca to c/world@lemmy.world

21 comments fedilink

Doctors are hailing “off the chart” trial results that show a new drug stopped lung cancer advancing for longer than any other treatment in medical history.

Lung cancer is the world’s leading cause of cancer death, accounting for about 1.8m deaths every year. Survival rates in those with advanced forms of the disease, where tumours have spread, are particularly poor.

More than half of patients (60%) diagnosed with advanced forms of lung cancer who took lorlatinib were still alive five years later with no progression in their disease, data presented at the world’s largest cancer conference showed. The rate was 8% in patients treated with a standard drug, the trial found.

The results are the longest progression-free survival (PFS) outcomes ever recorded in patients with non-small cell lung cancer, the world’s most common form of the disease. They were presented at the annual meeting of the American Society of Clinical Oncology (Asco) in Chicago on Friday.